acute myeloid leukemia (AML) | Aplastic Anemia & MDS International Foundation

acute myeloid leukemia (AML)

David Jacobsohn, MD, ScM

Jacobsohn, David
Division Chief, Blood and Marrow Transplanation
Children's National

David Jacobsohn, MD, ScM is the Division Chief, Blood and Marrow Transplanation at Children's National Hospital in Washington, D.C.   Previously, he was at Children’s Memorial Hospital in Chicago, where he served as a member of the Stem Cell Transplant Program staff and as the Director of the Chronic Graft-versus-Host Disease Clinic. He has lectured widely on GvHD/BMT in Europe, Latin America, and the United States. Dr.

Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp

Author(s): 
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M
Primary Author: 
Bejanyan N
Journal Title: 
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation
Original Publication Date: 
Sep 2020

Myeloablative (MAC) as compared to reduced-intensity conditioning (RIC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience

Author(s): 
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM
Primary Author: 
Bewersdorf JP
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Sep 2020

Mutations in the tumor suppressor gene TP53 are detected in 5-10% of patients with

Robert Collins, MD

Collins, Robert
Director of both the Hematologic Malignancies/Blood and Marrow Transplantation Program and the Combined Adult/Pediatric Stem Cell Transplant Program
Harold C. Simmons Comprehensive Cancer Center

A recognized leader in the field of adoptive immunotherapy, Dr. Collins specializes in blood and marrow transplantation and hematologic malignancies such as leukemia, lymphoma, myeloma, Hodgkin’s disease, and myelodysplasia.

Dr. Collins earned his medical degree from the University of Missouri-Kansas City School of Medicine. He completed an internal medicine residency at Baylor University Medical Center in Dallas, as well as a fellowship in hematology and oncology at the University of California at Los Angeles.

Vijaya Bhatt, MD

Bhatt, Vijaya
Associate Professor
University of Nebraska Medical Center

Dr. Vijaya Raj Bhatt graduated from Institute of Medicine, Tribhuvan University in Nepal in 2009 with a degree of Bachelor of Medicine and Bachelor of Surgery (MBBS). He then went on to do a three-year residency in internal medicine in Staten Island University Hospital in Staten Island, New York. During his residency, he was awarded the resident of the year for three consecutive years. After completing his residency, he joined the University of Nebraska Medical Center in Nebraska and completed his fellowship in hematology-oncology.